Laura Enyedi, MD
Ophthalmology · Durham, NCNPI 1710060975
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $4,675 of the $6,066 with a category attached, or 77.1%. 8 manufacturers reported payments, led by Coopervision Inc. at 41.2% of the total. Reporting peaked in 2022 at $2,529 and has fallen 84.4% since, to $394 in 2025.
Across 14 payments — averaging $433.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Coopervision Inc.$3K
- Novartis$2K
- Leadiant Biosciences, Inc.$500
- Dompe US, Inc.$353
- AbbVie$193
- Bausch & Lomb Americas Inc.$96
- plus $99 from 2 others
Across 16 payments — averaging $6356.92 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Ocular Therapeutix, Inc.$102K
What the payments were for
- Consulting fees$4,67577%
- Food & beverage$87314%
- Education$5008%
- Gifts$170%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Coopervision Inc. | 1 | $2,500 |
| Novartis | 3 | $2,324 |
| Leadiant Biosciences, Inc. | 1 | $500 |
| Dompe US, Inc. | 4 | $353 |
| AbbVie | 2 | $193 |
| Bausch & Lomb Americas Inc. | 1 | $96 |
| Harrow Eye, LLC | 1 | $82 |
| Carl Zeiss Meditec, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MiSight Contact Lens$2,500
- Oxervate$231
How this compares
$6,066 in reported general payments places this provider in the 85th percentile of 588 ophthalmology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Tobramycin-DexamethasoneTobramycin/Dexamethasone | 45 | $2,373 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Durham
- Julie WoodwardDurham$1M
- Lejla VajzovicDurham$681K
- Terry KimDurham$605K
- Leon HerndonDurham$230K
- Glenn JaffeDurham$218K
- Robin VannDurham$213K
- Anthony KuoDurham$186K
- Michael RichardDurham$113K
- Priyatham MettuDurham$111K
- Jason LissDurham$69K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.